Did you mean ispronicline of azd3409 of tc 1,2 of イスプロニクリン?
Displaying drugs 526 - 550 of 12637 in total
Vildagliptin
Vildagliptin (LAF237) is an orally active antihyperglycemic agent that selectively inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme. It is used to manage type II diabetes mellitus, where GLP-1 secretion and insulinotropic effects are impaired. By inhibiting DPP-4, vildagliptin prevents the degradation of glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP),...
Approved
Investigational
Matched Iupac: … (2S)-1-{2-[(3-hydroxyadamantan-1-yl)amino]acetyl}pyrrolidine-2-carbonitrile …
Matched Description: … [A232488] By inhibiting DPP-4, vildagliptin prevents the degradation of glucagon-like peptide 1 (GLP- ... Elevated levels of GLP-1 and GIP consequently results in improved glycemic control. ... (DPP-4) enzyme. …
Matched Categories: … Glucagon-Like Peptide 1 ... Heterocyclic Compounds, 1-Ring …
Matched Description: … [A232488] By inhibiting DPP-4, vildagliptin prevents the degradation of glucagon-like peptide 1 (GLP- ... Elevated levels of GLP-1 and GIP consequently results in improved glycemic control. ... (DPP-4) enzyme. …
Matched Categories: … Glucagon-Like Peptide 1 ... Heterocyclic Compounds, 1-Ring …
Influenza A virus A/Brisbane/02/2018 (H1N1) recombinant hemagglutinin antigen
A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence...
Approved
Matched Description: … memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. ... This defence includes the production of humoral immunity through the development of antibodies (through ... A seasonally-specific component of the influenza vaccine. …
Rimegepant
Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. It received FDA approval on February 27, 2020 for the acute treatment migraine headache, and was subsequently approved by the European Commission in April 2022 for both the treatment and prevention of migraines. While several parenteral antagonists...
Approved
Investigational
Matched Iupac: … [4,5-b]pyridin-1-yl}piperidine-1-carboxylate ... (5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-5H,6H,7H,8H,9H-cyclohepta[b]pyridin-9-yl 4-{2-oxo-1H,2H,3H-imidazo …
Matched Description: … Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. ... subsequently approved by the European Commission in April 2022 for both the treatment and prevention of ... [L41640] While several parenteral antagonists of CGRP and its receptor have been approved for migraine …
Matched Categories: … MATE 1 Inhibitors ... Heterocyclic Compounds, 1-Ring …
Matched Description: … Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. ... subsequently approved by the European Commission in April 2022 for both the treatment and prevention of ... [L41640] While several parenteral antagonists of CGRP and its receptor have been approved for migraine …
Matched Categories: … MATE 1 Inhibitors ... Heterocyclic Compounds, 1-Ring …
Rufinamide
Rufinamide is a triazole derivative and an anticonvulsant medication to treat seizure disorders like Lennox-Gastuat syndrome, a form of childhood epilepsy. Clinical trials suggest its efficacy in the treatment of partial seizures.
Approved
Matched Iupac: … 1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-triazole-4-carboxamide …
Matched Description: … Clinical trials suggest its efficacy in the treatment of partial seizures. ... derivative and an anticonvulsant medication to treat seizure disorders like Lennox-Gastuat syndrome, a form of …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Matched Description: … Clinical trials suggest its efficacy in the treatment of partial seizures. ... derivative and an anticonvulsant medication to treat seizure disorders like Lennox-Gastuat syndrome, a form of …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Baricitinib
Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune responses. Baricitinib was...
Approved
Investigational
Matched Iupac: … 2-[1-(ethanesulfonyl)-3-(4-{7H-pyrrolo[2,3-d]pyrimidin-4-yl}-1H-pyrazol-1-yl)azetidin-3-yl]acetonitrile …
Matched Description: … baricitinib for the treatment of COVID-19 in May 2022. ... By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune ... Baricitinib was first approved by the European Commission (EC) in February 2017 for the treatment of …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Matched Products: … โอลูเมียนท์ (4 มก.) ... UNAMİTY 4 MG FİLM KAPLI TABLET, 7 ADET ... UNAMİTY 4 MG FİLM KAPLI TABLET, 14 ADET …
Matched Description: … baricitinib for the treatment of COVID-19 in May 2022. ... By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune ... Baricitinib was first approved by the European Commission (EC) in February 2017 for the treatment of …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Matched Products: … โอลูเมียนท์ (4 มก.) ... UNAMİTY 4 MG FİLM KAPLI TABLET, 7 ADET ... UNAMİTY 4 MG FİLM KAPLI TABLET, 14 ADET …
Influenza A virus A/California/7/2009 X-179A (H1N1) hemagglutinin antigen (formaldehyde inactivated)
A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence...
Approved
Matched Description: … memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. ... This defence includes the production of humoral immunity through the development of antibodies (through ... A seasonally-specific component of the influenza vaccine. …
Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (formaldehyde inactivated)
A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence...
Approved
Matched Description: … memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. ... This defence includes the production of humoral immunity through the development of antibodies (through ... A seasonally-specific component of the influenza vaccine. …
Influenza A virus A/California/7/2009 X-179A (H1N1) hemagglutinin antigen (UV, formaldehyde inactivated)
A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence...
Approved
Matched Description: … memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. ... This defence includes the production of humoral immunity through the development of antibodies (through ... A seasonally-specific component of the influenza vaccine. …
Degarelix
Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH) which ultimately causes testosterone suppression. Reduction in...
Approved
Matched Iupac: … (4S)-N-{4-[(2S)-2-{[(1R)-2-[4-(carbamoylamino)phenyl]-1-{[(1S)-1-{[(2S)-1-[(2S)-2-{[(1R)-1-carbamoylethyl ... ]carbamoyl}pyrrolidin-1-yl]-1-oxo-6-[(propan-2-yl)amino]hexan-2-yl]carbamoyl}-3-methylbutyl]carbamoyl ... propanamido]-3-(pyridin-3-yl)propanamido]-3-hydroxypropanamido]ethyl]phenyl}-2,6-dioxo-1,3-diazinane-4- ... }ethyl]carbamoyl}-2-[(2S)-2-[(2R)-2-[(2R)-3-(4-chlorophenyl)-2-[(2R)-2-acetamido-3-(naphthalen-2-yl)propanamido …
Matched Description: … Degarelix is used for the treatment of advanced prostate cancer. ... Chemically, it is a synthetic linear decapeptide amide with seven unnatural amino acids, five of which …
Matched Description: … Degarelix is used for the treatment of advanced prostate cancer. ... Chemically, it is a synthetic linear decapeptide amide with seven unnatural amino acids, five of which …
Daridorexant
Daridorexant, formerly known as nemorexant, is a selective dual orexin receptor antagonist used to treat insomnia. Insomnia is characterized by difficulties with sleep onset and/or sleep maintenance and impairment of daytime functioning. It chronically affects the person's daily functioning and long-term health effects, as insomnia is often associated with comorbidities...
Approved
Matched Iupac: … 5-chloro-2-[(2S)-1-[5-methoxy-2-(2H-1,2,3-triazol-2-yl)benzoyl]-2-methylpyrrolidin-2-yl]-4-methyl-1H- …
Matched Description: … Insomnia is characterized by difficulties with sleep onset and/or sleep maintenance and impairment of ... Novel drugs that target orexin receptors gained increasing attention after discovering the role of orexin ... was designed via an intensive drug discovery program to improve the potency and maximize the duration of …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Matched Description: … Insomnia is characterized by difficulties with sleep onset and/or sleep maintenance and impairment of ... Novel drugs that target orexin receptors gained increasing attention after discovering the role of orexin ... was designed via an intensive drug discovery program to improve the potency and maximize the duration of …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Motixafortide
Motixafortide is a cyclic peptide hematopoietic stem cell mobilizer used to improve stem cell collection prior to autologous transplantation. Hematopoietic stem cell transplantation (HSCT) is commonly employed in the context of hematologic cancers - high-dose chemotherapy regimens destroy cancerous blood cells, which are then replaced via infusion of the patient's...
Approved
Investigational
Matched Description: … C-X-C Motif Chemokine Receptor 4 (CXCR4), a protein that helps to anchor stem cells to bone marrow matrix ... an adequate number of stem cells in ~92% of patients within two apheresis procedures, compared to ~26% ... of patients receiving only filgrastim. …
Tolcapone
Tolcapone is a drug that inhibits the enzyme catechol-O-methyl transferase (COMT). It is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa medication. It is a yellow, odorless, non-hygroscopic, crystalline compound. Tolcapone is associated with a risk of hepatotoxicity.
Approved
Withdrawn
Matched Synonyms: … 3,4-dihydroxy-4'-methyl-5-nitrobenzophenone ... 3,4-dihydroxy-5-nitro-4'-methylbenzophenone ... 4'-methyl-3,4-dihydroxy-5-nitrobenzophenone …
Matched Iupac: … 5-(4-methylbenzoyl)-3-nitrobenzene-1,2-diol …
Matched Description: … Tolcapone is associated with a risk of hepatotoxicity. ... It is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa medication. …
Matched Iupac: … 5-(4-methylbenzoyl)-3-nitrobenzene-1,2-diol …
Matched Description: … Tolcapone is associated with a risk of hepatotoxicity. ... It is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa medication. …
Propiolactone
Propiolactone is a lactone compound with a four-membered ring. It is a colorless liquid with a pungent slightly sweet odor. Propiolactone is a disinfectant used for the sterilization of blood plasma, vaccines, tissue grafts, surgical instruments, and enzymes. It has been used against bacteria, fungi, and virus. It is currently...
Approved
Withdrawn
Matched Description: … Propiolactone is a disinfectant used for the sterilization of blood plasma, vaccines, tissue grafts, …
Edetic acid
A chelating agent (chelating agents) that sequesters a variety of polyvalent cations. It is used in pharmaceutical manufacturing and as a food additive.
Approved
Vet approved
Matched Synonyms: … EDTA, ion(4-) ... (ethylenedinitrilo)tetraacetic acid, ion(4−) …
Matched Description: … A chelating agent (chelating agents) that sequesters a variety of polyvalent cations. …
Matched Description: … A chelating agent (chelating agents) that sequesters a variety of polyvalent cations. …
Metreleptin
Metreleptin, a recombinant analog of the human hormone leptin, is an orphan drug used to treat complications of leptin deficiency in people with lipodystrophy. Lipodystrophies include a range of disorders characterized by the reduction, absence, or altered distribution of adipose tissue. Complications of lipodystrophy include metabolic abnormalities such as hypertriglyceridemia,...
Approved
Matched Description: … of adipose tissue. ... [L41315] Administration of metreleptin results in improvement of metabolic symptoms including improvements ... of leptin deficiency in people with lipodystrophy. …
Diroximel fumarate
Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting forms of MS...
Approved
Investigational
Matched Iupac: … 1-[2-(2,5-dioxopyrrolidin-1-yl)ethyl] 4-methyl (2E)-but-2-enedioate …
Matched Description: … of both North America and Europe. ... More than 80% of patients suffering from this disease have relapsing-remitting MS. ... Relapsing-remitting forms of MS lead to neurological symptoms that resolve and recur periodically. …
Matched Description: … of both North America and Europe. ... More than 80% of patients suffering from this disease have relapsing-remitting MS. ... Relapsing-remitting forms of MS lead to neurological symptoms that resolve and recur periodically. …
Vinorelbine
Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC) . It was initially approved in the USA in 1990's for the treatment of NSCLC .
It is a third-generation vinca alkaloid. The introduction...
Approved
Investigational
Matched Iupac: … methyl (1R,9R,10S,11R,12R,19R)-11-(acetyloxy)-12-ethyl-4-[(12S,14R)-16-ethyl-12-(methoxycarbonyl)-1,10 …
Matched Description: … Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies ... genetics on the clearance of this drug [L2002]. ... It was initially approved in the USA in 1990's for the treatment of NSCLC [L2010]. …
Matched Products: … RENOVEL 10 MG/1 ML IV ENJEKSİYONLUK ÇÖZELTİ İÇEREN FLAKON, 1 ADET ... NAVELBINE 20 MG YUMUSAK KAPSUL, 1 ADET ... NAVELBINE 30 MG YUMUSAK KAPSUL, 1 ADET …
Matched Description: … Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies ... genetics on the clearance of this drug [L2002]. ... It was initially approved in the USA in 1990's for the treatment of NSCLC [L2010]. …
Matched Products: … RENOVEL 10 MG/1 ML IV ENJEKSİYONLUK ÇÖZELTİ İÇEREN FLAKON, 1 ADET ... NAVELBINE 20 MG YUMUSAK KAPSUL, 1 ADET ... NAVELBINE 30 MG YUMUSAK KAPSUL, 1 ADET …
Methimazole
Methimazole is a thionamide antithyroid agent that inhibits the synthesis of thyroid hormones.[A184559,A184733,A184694] It was first introduced as an antithyroid agent in 1949 and is now commonly used in the management of hyperthyroidism, particularly in those for whom more aggressive options such as surgery or radioactive iodine therapy are inappropriate.[L8336,L8339]...
Approved
Matched Synonyms: … 1-Methylimidazole-2(3H)-thione …
Matched Iupac: … 1-methyl-2,3-dihydro-1H-imidazole-2-thione …
Matched Description: … Methimazole is a thionamide antithyroid agent that inhibits the synthesis of thyroid hormones. ... first introduced as an antithyroid agent in 1949[A184502] and is now commonly used in the management of ... the pro-drug [carbimazole], which is an antithyroid medication used in the United Kingdom and parts of …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Matched Iupac: … 1-methyl-2,3-dihydro-1H-imidazole-2-thione …
Matched Description: … Methimazole is a thionamide antithyroid agent that inhibits the synthesis of thyroid hormones. ... first introduced as an antithyroid agent in 1949[A184502] and is now commonly used in the management of ... the pro-drug [carbimazole], which is an antithyroid medication used in the United Kingdom and parts of …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Moxidectin
Moxidectin is a potent, broad-spectrum endectocide (antiparasitic that is active against endo- and ecto-parasites) with activity against nematodes, insects, and acari. It was first used in cattle followed by an approved use in general animals. It is a semi-synthetic methoxine derivative of nemadectin which is a 16-member pentacyclic lactone of...
Approved
Investigational
Vet approved
Matched Iupac: … (1'R,2R,4E,4'S,5S,6S,8'R,10'E,13'R,14'E,16'E,20'R,21'R,24'S)-21',24'-dihydroxy-4-(methoxyimino)-5,11' ... ,13',22'-tetramethyl-6-(4-methylpent-2-en-2-yl)-3',7',19'-trioxaspiro[oxane-2,6'-tetracyclo[15.6.1.1^ …
Matched Description: … It is a semi-synthetic methoxine derivative of nemadectin which is a 16-member pentacyclic lactone of ... Moxidectin differs by the absence of a disaccharide moiety on carbon 13, a substituted olefinic side …
Matched Description: … It is a semi-synthetic methoxine derivative of nemadectin which is a 16-member pentacyclic lactone of ... Moxidectin differs by the absence of a disaccharide moiety on carbon 13, a substituted olefinic side …
Tepotinib
Tepotinib is a MET tyrosine kinase inhibitor intended to treat a variety of MET-overexpressing solid tumors. It was originally developed in partnership between EMD Serono and the University of Texas M.D. Anderson Cancer Center in 2009 and has since been investigated in the treatment of neuroblastoma, gastric cancers, non-small cell...
Approved
Investigational
Matched Iupac: … 3-{1-[(3-{5-[(1-methylpiperidin-4-yl)methoxy]pyrimidin-2-yl}phenyl)methyl]-6-oxo-1,6-dihydropyridazin …
Matched Description: … Tepotinib is a MET tyrosine kinase inhibitor intended to treat a variety of MET-overexpressing solid ... [A228058] It was originally developed in partnership between EMD Serono and the University of Texas M.D ... [A228058] MET is a desirable target in the treatment of certain solid tumors as it appears to play a …
Matched Categories: … MATE 1 Inhibitors ... Heterocyclic Compounds, 1-Ring …
Matched Description: … Tepotinib is a MET tyrosine kinase inhibitor intended to treat a variety of MET-overexpressing solid ... [A228058] It was originally developed in partnership between EMD Serono and the University of Texas M.D ... [A228058] MET is a desirable target in the treatment of certain solid tumors as it appears to play a …
Matched Categories: … MATE 1 Inhibitors ... Heterocyclic Compounds, 1-Ring …
Pralsetinib
Pralsetinib, similar to the previously approved selpercatinib, is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A219751, L15986] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers, including non-small cell lung cancer. Although multikinase inhibitors, including cabozantinib, ponatinib,...
Approved
Investigational
Matched Iupac: … (1s,4s)-N-[(1S)-1-[6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl]ethyl]-1-methoxy-4-{4-methyl-6-[(5-methyl ... -1H-pyrazol-3-yl)amino]pyrimidin-2-yl}cyclohexane-1-carboxamide …
Matched Description: … [A202049, A202055, L15986] Although a phase 1/2 trial of pralsetinib termed ARROW (NCT03037385) is ... still ongoing, pralsetinib was granted accelerated FDA approval on September 4, 2020, for the treatment ... RET RTK inhibitors for the treatment of RET-driven cancers. …
Matched Categories: … MATE 1 Inhibitors ... Heterocyclic Compounds, 1-Ring …
Matched Description: … [A202049, A202055, L15986] Although a phase 1/2 trial of pralsetinib termed ARROW (NCT03037385) is ... still ongoing, pralsetinib was granted accelerated FDA approval on September 4, 2020, for the treatment ... RET RTK inhibitors for the treatment of RET-driven cancers. …
Matched Categories: … MATE 1 Inhibitors ... Heterocyclic Compounds, 1-Ring …
Cedazuridine
Myelodysplastic syndromes (MDS) are a group of hematopoietic neoplasms that give rise to variable cytopenias progressing to secondary acute myeloid leukemia (sAML), which is invariably fatal if untreated.[A215082, A215092, A215097] Hypomethylating agents such as decitabine and azacitidine are used to treat MDS through inducing DNA hypomethylation and apoptosis of cancerous...
Approved
Investigational
Matched Iupac: … (4R)-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one …
Matched Description: … Myelodysplastic syndromes (MDS) are a group of hematopoietic neoplasms that give rise to variable cytopenias ... decitabine] and [azacitidine] are used to treat MDS through inducing DNA hypomethylation and apoptosis of ... tetrahydrouridine derivative specifically designed to inhibit CDA and facilitate oral administration of …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Matched Description: … Myelodysplastic syndromes (MDS) are a group of hematopoietic neoplasms that give rise to variable cytopenias ... decitabine] and [azacitidine] are used to treat MDS through inducing DNA hypomethylation and apoptosis of ... tetrahydrouridine derivative specifically designed to inhibit CDA and facilitate oral administration of …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Nilutamide
Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin that stimulate the growth of...
Approved
Investigational
Matched Synonyms: … 5,5-Dimethyl-3-(α,α,α-trifluoro-4-nitro-m-tolyl)hydantoin …
Matched Iupac: … 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]imidazolidine-2,4-dione …
Matched Description: … Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin that stimulate ... the growth of normal and malignant prostatic tissue. ... Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Matched Iupac: … 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]imidazolidine-2,4-dione …
Matched Description: … Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin that stimulate ... the growth of normal and malignant prostatic tissue. ... Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Salmeterol
Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, salbutamol. Salmeterol was first described in the literature in 1988. Salmeterol's structure...
Approved
Matched Iupac: … 4-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)-2-(hydroxymethyl)phenol …
Matched Description: … [A183737] Salmeterol was granted FDA approval on 4 February 1994.[L11542] ... long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of ... [L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 …
Matched Description: … [A183737] Salmeterol was granted FDA approval on 4 February 1994.[L11542] ... long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of ... [L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 …
Erythrityl tetranitrate
A vasodilator with general properties similar to nitroglycerin. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1020)
Approved
Experimental
Investigational
Displaying drugs 526 - 550 of 12637 in total